Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
A Phase II Study of Tegafur/Uracil (UFUR )Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary

ct scan
measurable disease
neutrophil count
thalidomide
hepatitis
  • 4 views
  • 07 Nov, 2020
  • 1 location
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

/metastatic HCC with Child-Pugh B7 liver disease who have received no prior systemic therapy.

  • 0 views
  • 10 Apr, 2021
  • 1 location
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

For the majority of patients, metastatic HCC is incurable and patients should be considered candidates for clinical trials when appropriate. Till recently there was no worldwide, approved

cancer
neutrophil count
measurable disease
gemcitabine
coumadin
  • 14 views
  • 07 Nov, 2020
  • 1 location
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

hepatocellular carcinoma who could not be radically cured and not receive any prior systemic therapy. The study will use PFS and OS as the co-primary endpoints, with approximately 280 patients planned to be

  • 0 views
  • 03 Feb, 2021
  • 1 location
Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma

, additional preoperative intra- and extra-hepatic early or metastatic HCC unseen or equivocal with conventional imaging (CT and MRI) and responsible for recurrence or disease progression at 6 months.

  • 1 views
  • 31 Jan, 2021
  • 5 locations
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression

TACE
metastatic hepatocellular carcinoma
lenvatinib
hepatitis
chemoembolization
  • 79 views
  • 11 Apr, 2021
  • 152 locations
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

metastatic hepatocellular carcinoma, HCC). Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the

  • 0 views
  • 19 Mar, 2021
  • 44 locations
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different …

tumor cells
cancer
carboplatin
cancer therapy
fluorouracil
  • 178 views
  • 27 Mar, 2021
  • 136 locations
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

This study will evaluate the safety and efficacy of durvalumab in combination with lenvatinib in participants with locally advanced hepatocellular carcinoma before liver transplant and metastatic unresectable HCC.The primary hypothesis of this study are that patients with locally advanced HCC could benefit from durvalumab plus lenvatinib before liver transplant; patients …

ct scan
lenvatinib
international normalized ratio
durvalumab
ejection fraction
  • 0 views
  • 26 Jan, 2021
  • 1 location
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

Hepatocellular carcinoma (HCC) is a common malignancy, and more than 70% of newly diagnosed HCC patients already have advanced disease. Sorafenib and lenvatinib are recommended as first-line options for advanced HCC. The PD-1 monoclonal antibodysuch as nivolumab and pembrolizumab, have been approved to treat the patients with advanced HCC by …

  • 0 views
  • 26 Jan, 2021
  • 1 location